

The 67th

Virtual Annual Conference
of the Israel Heart Society
In association with
the Society of Cardiothoracic Surgery

Satellite Sessions

October 19 | 12:45-13:45



Abbot Laboratories | October 19 | 12:45-13:45 Structural Heart – Tailored Therapy for Every Patient

Click here to access the session



Novartis Israel | October 19 | 12:45-13:45 Dilemmas in CV Risk Management

Click here to access the session



Novo Nordisk | October 19 | 12:45-13:45 ASCVD & T2D: Bridging the Evidence into Clinical Practice

Click here to access the session



Bayer Israel | October 19 | 12:45-13:45 Diabetes Mellitus – Implications for Patients with Cardiovascular Disease

Click here to access the session

October 19 | 20:00-21:00



Novartis Israel | October 19 | 20:00-21:00 Evolution of RNAi Therapies

Click here to access the session

October 20 | 12:45-13:45



AstraZeneca (Israel) | October 20 | 12:45-13:45 A New Era in HF and Renal Disease Modification with sglt2i's

Click here to access the session



Sanofi | October 20 | 12:45-13:45

Is there more to hyper-cholesterolemia management than LDL reduction?

Sub analyses of high risk groups from the Odyssey Outcome trial

Click here to access the session



Pfizer Pharmaceuticals Israel | October 20 | 12:45-13:45 Where are the ATTR-CM patients? How to recognize and diagnose them

Click here to access the session

October 20 | 16:15-17:15



Pfizer Pharmaceuticals Israel | October 20 | 16:15-17:15 How AI meets AF – Innovative Technologies for AF Detection

Click here to access the session



Novo Nordisk | October 20 | 16:15-17:15 Managing the burden of cardiovascular disease: time to focus on obesity care

Click here to access the session